A Rainforest Clue for ALS
Longevity Medicine

A Rainforest Clue for ALS

Nov 22 2026

Edited and approved by Stephen C. Rose, PhD, MS

A compound found in a rainforest tree helped human motor neurons withstand a laboratory stress that usually damages them. The more interesting finding came when investigators tested a different compound that acts on one of the same proteins. It also protected cultured neurons, giving the researchers another way to investigate a possible treatment target. The study used cells grown from human donors, including people with several forms of amyotrophic lateral sclerosis, or ALS. It measured what happened in those cells. Whether the same approach can preserve movement or slow disease in people remains unknown. [1]

ALS progressively damages motor neurons, the cells that send instructions to muscles. As more of those neurons fail, people can lose strength and have trouble speaking, swallowing or breathing. Some cases are linked to identifiable inherited changes. Many have no clear family history. This diversity poses a practical question for drug development. Could a treatment help motor neurons survive across several forms of the disease by improving a stress response they share? [1] [2]

What researchers put in the dish

Simon Maksour and colleagues used induced pluripotent stem cells. These start as mature cells that are returned to a state where they can develop into different cell types. Researchers can then direct them to become spinal motor neurons. A cell line gives scientists a continuing supply of cells with a particular genetic background, so they can repeat an experiment and look for differences among donors. It also gives them access to the cell type that is most difficult to sample directly from people with ALS. [1]

To make damage measurable in a short experiment, the researchers exposed cultured neurons to bortezomib. This drug inhibits the proteasome, one of the systems cells use to break down proteins. Interfering with that system adds a specific kind of stress. The team watched the cells over time and measured both viability and the length of neurites, the extensions that let neurons connect with other cells. The model put the neurons under a challenge they could compare across wells. ALS in a person develops over a much longer time and involves surrounding cells, muscles and the wider nervous system. Those interactions are largely missing in this test. [1]

Researchers screened 512 natural compounds from plants, fungi and marine sources. Two promising leads, hopeaphenol and vaticanol B, came from the tree Anisoptera thurifera. They belong to a group of compounds made of four linked units related to resveratrol. Both performed better than resveratrol under the study conditions, and hopeaphenol showed the stronger effects in the initial comparisons. The result illustrates an advantage of testing the compounds side by side. Closely related molecules can behave quite differently in the same cells. [1]

What protection meant in this experiment

In the follow-up experiment, the researchers used 14 cell lines. Six were from people with sporadic ALS and four represented familial forms involving the genes TARDBP, SOD1 or C9ORF72. The panel also included three healthy comparison lines and one line in which a TARDBP variant had been corrected. Under the imposed stress, hopeaphenol significantly improved the viability measurement in 12 of the 14 lines. Those 14 lines represent the entire test panel, including comparison cells. Each response was a change in the cells’ ability to survive a specific challenge in a dish. [1]

Timing mattered. When the team added hopeaphenol early, it helped preserve the neurons’ extensions. Adding it after substantial damage had already taken place did little to restore their length in the two lines examined in that experiment. Researchers also measured changes in electrical activity, including how some neurons responded to stimulation and fired repeatedly. The effects varied among lines and across electrical measurements. A compound that helps protect cells under stress and changes some of their firing properties merits further investigation, while repair of an already damaged connection remains a separate goal. [1]

Why the second compound matters

The team investigated SIRT1, a protein that helps regulate how cells respond to metabolic and other stresses. SIRT1 changes the activity of other proteins by removing a small chemical group called an acetyl group. The authors found evidence that this pathway contributed to the protection they saw. They also tested SRT2104, an experimental small molecule that activates SIRT1. In selected motor neuron cultures, SRT2104 protected neurites and affected some abnormal electrical properties at roughly one-third the concentration of hopeaphenol used for comparison. That is a laboratory comparison. A dose that reaches motor neurons safely in a person would have to be established separately. [1]

Hopeaphenol itself presents a delivery question. A promising drug must reach the brain and spinal cord at a level it can sustain safely. The chemical properties of hopeaphenol suggest it may have difficulty crossing the barrier between blood and the central nervous system. SRT2104 has been studied in animals for neurological effects and in a small early safety and drug-exposure study in older volunteers. That human study helps describe what happens to the drug after dosing. It did not evaluate treatment of ALS or establish that it reaches human motor neurons at levels sufficient to protect them. [1] [3]

From a cell result to an ALS trial

The next question is whether the signal holds in models that represent other parts of the disease, such as the cells that support and surround motor neurons. Researchers would also want to determine whether SIRT1 activity actually changed where it mattered, how much of the protection depended on that change, and whether a compound stayed active without unacceptable effects elsewhere in the body. A result that holds across several forms of ALS would help justify a broader trial. The 14-line panel is a beginning, given the many patterns of disease progression and variation among individuals. [1]

In a clinical study, the outcomes would need to matter to patients. Investigators might track whether people retain abilities such as speaking, walking and swallowing, as well as breathing function and survival. They would also need a comparison group to account for the wide variation in how quickly ALS progresses. Measures from blood or spinal fluid could help interpret what a drug is doing, while patient outcomes would tell us whether that change translates into a benefit. The move from a cell plate to a patient trial is where many promising ideas have to be reconsidered. [1] [2]

It would also help to know when in the disease an intervention can make a difference. The cell experiments suggest timing deserves attention. In people, evaluating that question would require tracking when symptoms began and how much function they had already lost when they joined a trial. [1] [2]

How you may be able to benefit

For someone living with ALS, the practical value of this research is knowing what kind of evidence to look for. A headline about protection of human neurons may refer to donated cells grown in a lab. Ask whether a study enrolled people with ALS and whether it measured changes in daily function. The comparison with resveratrol in this experiment offers no evidence that taking resveratrol or a rainforest extract can slow the disease. [1]

An ALS care team can discuss treatments available now, including riluzole and edaravone where appropriate. In the United States, tofersen is approved for adults with ALS associated with a mutation in SOD1. Genetic counseling and testing can help determine whether such a targeted treatment or a particular trial applies. Speech, nutrition, mobility and respiratory care can also support day-to-day function. The prospect of a future treatment that works across several forms of ALS is worth following alongside the options people and their clinicians can use today. [2] [4]

References

[1] Maksour S, Do-Ha D, Fernandopulle N, et al. Phenotypic screening in ALS motor neurons identifies SIRT1 activation as a genotype-independent neuroprotective strategy. Cell Death Dis. Published October 31, 2026. doi:10.1038/s41419-026-09384-8.

[2] National Institutes of Health. Amyotrophic Lateral Sclerosis (ALS). Accessed November 15, 2026.

[3] Libri V, Brown AP, Gambarota G, et al. A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS One. 2012;7(12):e51395. doi:10.1371/journal.pone.0051395.

[4] U.S. Food and Drug Administration. FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene. Accessed November 15, 2026.

Scientific & Medical Editorial Standards

Content published by LongevityWiz is developed and reviewed by qualified scientific and medical professionals, including experts holding doctorates in Bioengineering and Immunology and a physician who is a Fellow of the American College of Cardiology (FACC). Our editorial approach emphasizes scientific accuracy, peer-reviewed research, and evidence-based health information. Content is provided for educational purposes only and does not constitute individualized medical advice. Read our full Medical Disclaimer. LongevityWiz does not provide personalized healthcare guidance. Always consult a physician or other qualified healthcare professional before changing your diet, exercise routine, medications, supplements or overall healthcare plan. Never disregard professional medical advice or delay seeking treatment because of information you have read on this website.

Continue